Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
Hepatology Research2022Vol. 52(8), pp. 721–729
Citations Over TimeTop 10% of 2022 papers
Yan‐Jun Xiang, Kang Wang, Hongming Yu, Xiaowei Li, Yuqiang Cheng, Weijun Wang, Jin‐Kai Feng, Meng‐Han Bo, Yingyi Qin, Yitao Zheng, Yunfeng Shan, Liping Zhou, Jian Zhai, Shuqun Cheng
Abstract
The combination of TACE with a PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in significantly improved clinical outcomes with a manageable safety profile compared with TACE with a PD-1 inhibitor.
Related Papers
- → Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma(2021)38 cited
- → Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma(2020)12 cited
- → A useful case of tumor resection and monitoring the blood concentration at lenvatinib therapy for multiple hepatocellular carcinoma(2021)2 cited
- → Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib(2022)1 cited
- → Associations between plasma concentrations of lenvatinib and angiopoietin and clinical responses to lenvatinib therapy in Japanese patients with thyroid cancer(2021)